CEFTRIAXONE SODIUM

Ceftriaxone Sodium Adverse Events Reported to the FDA Over Time

How are Ceftriaxone Sodium adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Ceftriaxone Sodium, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Ceftriaxone Sodium is flagged as the suspect drug causing the adverse event.

Most Common Ceftriaxone Sodium Adverse Events Reported to the FDA

What are the most common Ceftriaxone Sodium adverse events reported to the FDA?

Pyrexia	423 (1.81%)
Renal Failure Acute	375 (1.61%)
Rash	311 (1.33%)
Dyspnoea	266 (1.14%)
Pruritus	229 (.98%)
Anaphylactic Shock	224 (.96%)
Toxic Epidermal Necrolysis	219 (.94%)
Thrombocytopenia	217 (.93%)
Renal Failure	204 (.87%)
Drug Rash With Eosinophilia And Sys...	200 (.86%)
Urticaria	184 (.79%)
	Show More
Cholelithiasis	179 (.77%)
Hypotension	175 (.75%)
Stevens-johnson Syndrome	171 (.73%)
Erythema	167 (.72%)
Vomiting	163 (.7%)
Diarrhoea	157 (.67%)
Nausea	138 (.59%)
Pneumonia	135 (.58%)
Drug Interaction	133 (.57%)
Sepsis	133 (.57%)
Cardiac Arrest	127 (.54%)
Anaphylactic Reaction	125 (.54%)
Hypersensitivity	123 (.53%)
Pancytopenia	121 (.52%)
Acute Respiratory Distress Syndrome	119 (.51%)
Abdominal Pain	117 (.5%)
Respiratory Failure	116 (.5%)
Confusional State	114 (.49%)
Multi-organ Failure	114 (.49%)
Alanine Aminotransferase Increased	112 (.48%)
Anaemia	112 (.48%)
Cytolytic Hepatitis	110 (.47%)
Eosinophilia	110 (.47%)
Rash Maculo-papular	110 (.47%)
Tachycardia	110 (.47%)
Condition Aggravated	105 (.45%)
Shock	105 (.45%)
Aspartate Aminotransferase Increase...	104 (.45%)
Neutropenia	104 (.45%)
Liver Disorder	103 (.44%)
General Physical Health Deteriorati...	100 (.43%)
International Normalised Ratio Incr...	100 (.43%)
Blood Creatinine Increased	98 (.42%)
Convulsion	97 (.42%)
Death	95 (.41%)
Septic Shock	94 (.4%)
Agranulocytosis	92 (.39%)
Cholestasis	90 (.39%)
Drug Hypersensitivity	90 (.39%)
Clostridium Difficile Colitis	88 (.38%)
Disseminated Intravascular Coagulat...	88 (.38%)
Gamma-glutamyltransferase Increased	85 (.36%)
Haemolysis	84 (.36%)
Blood Pressure Decreased	83 (.36%)
Chills	81 (.35%)
Dehydration	80 (.34%)
Haemoglobin Decreased	79 (.34%)
Dermatitis Exfoliative	78 (.33%)
Headache	78 (.33%)
Cough	77 (.33%)
Drug Eruption	77 (.33%)
Haemolytic Anaemia	77 (.33%)
Oedema Peripheral	73 (.31%)
Rash Erythematous	73 (.31%)
Acute Generalised Exanthematous Pus...	72 (.31%)
Blood Alkaline Phosphatase Increase...	72 (.31%)
Asthenia	71 (.3%)
Hepatitis	71 (.3%)
Toxic Skin Eruption	71 (.3%)
Drug Ineffective	70 (.3%)
Loss Of Consciousness	70 (.3%)
Erythema Multiforme	69 (.3%)
Malaise	69 (.3%)
Leukopenia	68 (.29%)
Tremor	68 (.29%)
Cardio-respiratory Arrest	65 (.28%)
Dermatitis Bullous	65 (.28%)
Platelet Count Decreased	65 (.28%)
Blister	64 (.27%)
Coma	64 (.27%)
Dizziness	64 (.27%)
Arthralgia	63 (.27%)
Oedema	63 (.27%)
Skin Exfoliation	63 (.27%)
Hepatic Function Abnormal	61 (.26%)
Pain	61 (.26%)
Pancreatitis	61 (.26%)
Cardiac Failure	60 (.26%)
Agitation	59 (.25%)
Altered State Of Consciousness	59 (.25%)
Depressed Level Of Consciousness	59 (.25%)
Rash Generalised	59 (.25%)
Respiratory Distress	59 (.25%)
Gastrointestinal Haemorrhage	58 (.25%)
Pleural Effusion	58 (.25%)
Somnolence	58 (.25%)
Hyperhidrosis	56 (.24%)
Inflammation	56 (.24%)
Overdose	56 (.24%)
Hypoglycaemia	54 (.23%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Ceftriaxone Sodium, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Ceftriaxone Sodium is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Ceftriaxone Sodium

What are the most common Ceftriaxone Sodium adverse events reported to the FDA?

Epidermal And Dermal Conditions	2582 (11.06%)
Hepatic And Hepatobiliary	958 (4.1%)
Infections - Pathogen Unspecified	922 (3.95%)
Respiratory	909 (3.89%)
Renal Disorders	884 (3.79%)
Neurological	777 (3.33%)
Hematology Investigations	685 (2.93%)
Allergic Conditions	607 (2.6%)
Gastrointestinal Signs	568 (2.43%)
Cardiac Arrhythmias	558 (2.39%)
Bacterial Infectious	530 (2.27%)
	Show More
Body Temperature Conditions	480 (2.06%)
Hepatobiliary	476 (2.04%)
White Blood Cell	459 (1.97%)
Lower Respiratory Tract Disorders	387 (1.66%)
Decreased And Nonspecific Blood Pre...	319 (1.37%)
Anemias Nonhemolytic And Marrow Dep...	313 (1.34%)
Therapeutic And Nontherapeutic Effe...	281 (1.2%)
Cardiac And Vascular Investigations	269 (1.15%)
Gallbladder	249 (1.07%)
Platelet	248 (1.06%)
Angiedema And Urticaria	223 (.96%)
Gastrointestinal Motility And Defec...	211 (.9%)
Renal And Urinary Tract Investigati...	203 (.87%)
Hemolyses And Related Conditions	192 (.82%)
Movement Disorders	190 (.81%)
Electrolyte And Fluid Balance Condi...	177 (.76%)
Enzyme	168 (.72%)
Seizures	168 (.72%)
Bronchial Disorders	165 (.71%)
Oral Soft Tissue Conditions	162 (.69%)
Skin Vascular Abnormalities	162 (.69%)
Medication Errors	161 (.69%)
Deliria	160 (.69%)
Joint	148 (.63%)
Muscle	148 (.63%)
Urinary Tract Signs	148 (.63%)
Coagulopathies And Bleeding Diathes...	147 (.63%)
Heart Failures	146 (.63%)
Fungal Infectious	142 (.61%)
Musculoskeletal And Connective Tiss...	135 (.58%)
Gastrointestinal Hemorrhages	134 (.57%)
Viral Infectious	133 (.57%)
Upper Respiratory Tract Disorders	121 (.52%)
Vascular	118 (.51%)
Microbiology And Serology	113 (.48%)
Central Nervous System Vascular	111 (.48%)
Fatal Outcomes	110 (.47%)
Injuries	110 (.47%)
Anxiety Disorders	107 (.46%)
Exocrine Pancreas Conditions	105 (.45%)
Administration Site Reactions	103 (.44%)
Physical Examination Topics	98 (.42%)
Glucose Metabolism Disorders	94 (.4%)
Metabolic, Nutritional And Blood Ga...	93 (.4%)
Cardiac Disorder Signs	88 (.38%)
Encephalopathies	80 (.34%)
Headaches	80 (.34%)
Hematological And Lymphoid Tissue T...	80 (.34%)
Appetite And General Nutritional	77 (.33%)
Skin Appendage Conditions	76 (.33%)
Acid-base	74 (.32%)
Nephropathies	74 (.32%)
Pleural	74 (.32%)
Spleen, Lymphatic And Reticulendoth...	72 (.31%)
Gastrointestinal Inflammatory Condi...	67 (.29%)
Water, Electrolyte And Mineral	66 (.28%)
Protein And Chemistry Analyses	65 (.28%)
Ureteric	64 (.27%)
Disturbances In Thinking	63 (.27%)
Peritoneal And Retroperitoneal Cond...	61 (.26%)
Pulmonary Vascular	61 (.26%)
Immunology And Allergy	60 (.26%)
Ocular Infections, Irritations And ...	60 (.26%)
Coronary Artery	58 (.25%)
Cardiac Valve	57 (.24%)
Myocardial	56 (.24%)
Vascular Hemorrhagic	53 (.23%)
Urolithiases	51 (.22%)
Vision	51 (.22%)
Gastrointestinal Ulceration And Per...	50 (.21%)
Bile Duct	49 (.21%)
Mental Impairment	47 (.2%)
Tongue Conditions	47 (.2%)
Bone Disorders	45 (.19%)
Psychiatric	45 (.19%)
Vascular Hypertensive	45 (.19%)
Embolism And Thrombosis	44 (.19%)
Toxicology And Therapeutic Drug Mon...	44 (.19%)
Immune	43 (.18%)
Procedural And Device Related Injur...	42 (.18%)
Eye	41 (.18%)
Chemical Injury And Poisoning	40 (.17%)
Depressed Mood Disorders	38 (.16%)
Gastrointestinal	38 (.16%)
Hearing	37 (.16%)
Peripheral Neuropathies	37 (.16%)
Bone And Joint Injuries	36 (.15%)
Arteriosclerosis, Stenosis, Vascula...	34 (.15%)
Immunodeficiency Syndromes	33 (.14%)
Skin And Subcutaneous Tissue	33 (.14%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Ceftriaxone Sodium, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Ceftriaxone Sodium is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.